血清肝纤维化指标酶联免疫分析实验和增强化学发光免疫分析系统检测的评价

目的 评价增强化学发光免疫分析系统(Enhanced Chemiluminescence Immunoassay, ECLIA)与酶联免疫吸附试验(ELISA),测定血清透明质酸(HA)、层黏蛋白含量(LN)、Ⅳ型胶原(Ⅳ-C)和Ⅲ型前胶原(PCⅢ)方法与患者肝纤维化程度的相关性.方法 以患者肝穿病理结果为金标准,分别用ECLIA和ELISA法检测253例患者的4项血清纤维化指标,并分别与病理结果进行比较.结果 两种方法的检测结果均能反映患者从肝炎到肝硬化的肝纤维化逐渐加重的趋势.但与ELISA法比较,ECLIA方法检测的结果与病理结果的相关性较好.结论 ECLIA系统检测血清肝纤维化四项指标,可以更好的反应肝硬化的发展程度.

Evaluation of the ELISA and the Enhanced Chemiluminescence Immunoassay in use to determine the serum markers for liver fibrosis

Objective To evaluate the detection method of ELISA and Enhanced Chemiluminescence Immunoassay (ECLIA) in use to determine serum hyaluronate acid (HA), hminin (LN), typeⅣ collagen (IV-C) and type Ⅲ procollagen (PC Ⅲ ). Methods 253 patients with chronic hepatitis B were determined the four liver fibrosis serum markers with both the ECLIA and ELISA, and then compared with pathology results separately. Results Both the detection results of ELISA and ECLIA can reflect that the patient's liver fibrosis from hepatitis to liver cirrhosis aggravated gradually. Compared with ELISA, the results of ECLIA and pathology have a better correlation. Conclusions The detection of four liver fibrosis serum markers by ECLIA could indicate the better the response of the state of live fibrosis.